Luigetti, Marco http://orcid.org/0000-0001-7539-505X
Quan, Dianna
Berk, John L.
Conceição, Isabel
Misumi, Yohei
Chao, Chi-Chao
Bender, Shaun
Aldinc, Emre
Vest, John
Adams, David
Funding for this research was provided by:
Alnylam Pharmaceuticals
Article History
Received: 6 December 2023
Accepted: 21 February 2024
First Online: 21 March 2024
Declarations
:
: The HELIOS-A study (NCT03759379) was conducted in accordance with the International Conference of Harmonisation guidelines for Good Clinical Practice, local regulatory requirements, and the principles of the Declaration of Helsinki. The study was approved by Ethics Committees or Institutional Review Boards for each study site (listed in the Supplementary Material), and all patients provided written informed consent.
: Marco Luigetti reports consulting fees and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Alnylam Pharmaceuticals, Pfizer, and Sobi. Dianna Quan reports research funding from Alnylam Pharmaceuticals, Avidity Biosciences, Cytokinetics, Ionis Pharmaceuticals, Janssen Pharmaceuticals (formerly Momenta Pharmaceuticals), Pfizer, and Viela Bio, and consulting fees from Alnylam Pharmaceuticals and Ionis Pharmaceuticals. John L. Berk reports research funding from Alnylam Pharmaceuticals, AstraZeneca, Eidos Therapeutics, and Ionis Pharmaceuticals, consulting fees from Alnylam Pharmaceuticals, AstraZeneca, Eidos Therapeutics, Intellia Therapeutics, and Ionis Pharmaceuticals, and data safety monitoring and/or advisory board membership for Alnylam Pharmaceuticals, AstraZeneca, Corino Therapeutics, Intellia Therapeutics, and Ionis Pharmaceuticals. Isabel Conceição reports consulting fees from Alnylam Pharmaceuticals, AstraZeneca, Pfizer, and Sobi, payment or honoraria for lectures, presentations, speakers bureaus, or educational events from Akcea Therapeutics, Alnylam Pharmaceuticals, AstraZeneca, and Pfizer, and data safety monitoring and/or advisory board membership for Akcea Therapeutics, Alnylam Pharmaceuticals, and Intellia Therapeutics. Yohei Misumi reports research funding and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Alnylam Pharmaceuticals and Pfizer. Chi-Chao Chao has nothing to disclose. Shaun Bender, Emre Aldinc, and John Vest are all employees of Alnylam Pharmaceuticals. Emre Aldinc and John Vest report ownership of equity in Alnylam Pharmaceuticals. David Adams reports consulting fees from Alnylam Pharmaceuticals and AstraZeneca.